Population-based study of screening test performance indices of three human papillomavirus DNA tests

Journal of Medical Virology

Volumn 79, Issue 8, 2007, Pages 1169-1175

  Wahlström, Cecilia ^a   Iftner, Thomas ^b   Dillner, Joakim ^a   Dillner, Lena ^a,c  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cervical cancer; Longitudinal cohort study; PCR

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CANCER RISK; DEVICE; DOT HYBRIDIZATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PREVALENCE; SCREENING TEST; UTERINE CERVIX CARCINOMA IN SITU; VIRUS CARCINOGENESIS; VIRUS DETECTION; WART VIRUS;

ALPHAPAPILLOMAVIRUS; DNA, VIRAL; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; POPULATION SURVEILLANCE; SWEDEN;

HUMAN PAPILLOMAVIRUS;

EID: 34347334426     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20898     Document Type: Article

References (23)

1. Bergeron C, Jeannel D, Poveda J, Cassonnet P, Orth G. 2000. Human papillomavirus testing in women with mild cytologic atypia. Obstet Gynecol 95:821-827.
2. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman M, Moreno V, Kurman R, Shah KV. Group IBSoCCS. 1995. Prevalence of Human Papillomavirus in cervical cancer: A worldwide perspective. J Natl Cancer Inst 87:796-802.
3. Castle PE, Schiffman M, Gravitt PE, Kendall H, Fishman S, Dong H, Hildesheim A, Herrero R, Bratti MC, Sherman ME, Lorincz A, Schussler JE, Burk RD. 2002. Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol 68:417-423.
4. Cuschieri KS, Cubie HA. 2005. The role of human papillomavirus testing in cervical screening. J Clin Virol 32:S34-42.
5. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, Gie C, Ho L, Jacobs I, Pickles C, Sasieni P. 2003. Management of women who test positive for high-risk types of human papillomavirus: The HART study. Lancet 362:1871-1876.
6. Elfgren K, Kalantari M, Moberger B, Hagmar B, Dillner J. 2000. A population-based five-year follow-up study of cervical human papillomavirus infection. Am J Obstet Gynecol 183:561-567.
7. Forslund O, Antonsson A, Edlund K, van den Brule AJ, Hansson BG, Meijer CJ, Ryd W, Rylander E, Strand A, Wadell G, Dillner J, Johansson B. 2002. Population-based type-specific prevalence of high-risk human papillomavirus infection in middle-aged Swedish women. J Med Virol 66:535-541.
8. Ham Mv, Bakkers J, Harbers G, Quint W, Massuger L, Melchers W. 2005. Comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders. J Clin Microbiol 43:2662-2667.
9. Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. 1998. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338:423-428.
10. Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer C J, Walboomers JMM. 1997. A general primer GP5+/GP6+ -mediated PCR-enzyme immunoassay method for rapid detection of 14 high risk and 6 low risk human papillomavirus types in cervical scrapings. J Clin Microbiol 35:791-795.
11. Jacobs MV, Snijders PJF, Vorhorst FJ, Dillner J, Forslund O, Johansson B, von Knebel Doeberitz M, Meijer CJLM, Meyer T, Nindl I, Pfister H, Stockfleth E, Strand A, Wadell G, Walboomers JM. 1999. Reliable high risk HPV DNA testing by polymerase chain reaction: An intermethod and intramethod comparison. J Clin Pathol 52:498-503.
12. Kulasingam S, Hughes J, Kiviat N, Mao C, Weiss N, Kuypers J, Koutsky L. 2002. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 288:1749-1757.
13. Landis J, Koch G. 1977. The measurement of observer agreement for categorical data. Biometrics 33:159-174.
14. Monsonego J, Bohbot J, Pollini G, Krawec C, Vincent C, Merignargues I, Haroun F, Sednaoui P, Monfort L, Dachez R, Syrjänen K. 2005. Performance of the Roche AMPLICOR human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear. Gynecol Oncol 99:160-168.
15. Munoz N, Bosch FX, Sanjose Sd, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518-527.
16. Myers ER, McCrory DC, Subramanian S, McCall N, Nanda K, Datta S, Matchar DB. 2000. Settingthe target for a better cervical screening test: Characteristics of a cost-effective test for cervical neoplasia screening. Obstet Gynecol 96:645-652.
17. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJ. 1999. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 354:20-25.
18. Poljak M, Marin I, Seme K, Vince A. 2002. Hybrid Capture II HPV Test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J Clin Virol 25:S89-97.
19. Renshaw A. 2002. Measuring sensitivity in gynecologic cytology: A review. Cancer 96:210-217.
20. Schlecht N, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura R, Duarte-Franco E, Rohan T, Ferenczy A, Villa L, Franco E. 2001. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 286:3106-3114.
21. Söderlund-Strand A, Rymark P, Andersson P, Dillner J, Dillner L. 2005. Comparison between the Hybrid Capture II test and a PCR-based human papillomavirus detection method for diagnosis and posttreatment follow-up of cervical intraepithelial neoplasia. J Clin Microbiol 43:3260-3266.
22. Solomon D, Schiffman M, Tarone R. 2001. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 93:293-299.
23. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19.